Treatment, long-term outcome and prognostic variables in 214 unselected AML patients in Sweden

With the aim of describing an unselected series of acute myeloid leukaemias (AML) in adults, patients diagnosed 1987–1992 in the Örebro region of central Sweden were reviewed by

investigating hospital records. By utilizing: (1) The Swedish Cancer Registry, (2) The Cause of Death Registry, (3) listings of pathology bone marrow reports and (4) listings of inpatient

discharge diagnoses, we attempted to find all patients. Among secondary AML, only blast-crises of CML were excluded. A total of 214 cases of AML with a median age of 69.5 years were verified

corresponding to a mean yearly incidence in adults of 5.4/100 000. Of all patients, 56% had received ‘high-dose’ induction treatment, 28% ‘low-dose’ treatment and 16% no cytostatic

treatment. Median survival for all patients was 5.8 months and the probability of survival at 5 years was 9.3%. The 120 ‘high-dose’ treated patients had a total CR rate of 67%, median CR

duration 10.1 months and median survival 11.4 months. Age, LDH and kidney function were found to be independent prognostic variables for survival. The inclusion of patients unreferred from

district hospitals makes this study unique as an example of unselected AML. © 2000 Cancer Research Campaign

This paper was modified 12 months after initial publication to switch to Creative Commons licence terms, as noted at publication

Bassan R, Buelli M, Viero P, Minotti C and Barbui T (1992) The management of acute myelogenous leukemia in the elderly: ten year experience in 118 patients. Hematol Oncol 10: 251–260

From twelve months after its original publication, this work is licensed under the Creative Commons Attribution-NonCommercial-Share Alike 3.0 Unported License. To view a copy of this

license, visit http://creativecommons.org/licenses/by-nc-sa/3.0/

Anyone you share the following link with will be able to read this content: